Novel low dose pharmaceutical compositions comprising nimesulide, preparation and use thereof

A low-dose, solvate technology, applied in the field of preparation of this dosage form, can solve the problems of poor water solubility and wettability

Inactive Publication Date: 2009-05-13
PANACEA BIOTEC
View PDF1 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The poor water solubility and wettability of the drug poses problems for the preparation of drug formulations with good release and invariable bioavailability

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel low dose pharmaceutical compositions comprising nimesulide, preparation and use thereof
  • Novel low dose pharmaceutical compositions comprising nimesulide, preparation and use thereof
  • Novel low dose pharmaceutical compositions comprising nimesulide, preparation and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0022] Nimesulide is routinely administered as 100-200 mg tablets or capsules twice a day, or as a 50 mg / ml suspension for the treatment of inflammatory conditions, pain, arthritis and the like. High dose compositions of nimesulide are associated with dose-related side effects such as gastric or hepatotoxicity, even some heart diseases or any other condition due to enzymatic inhibition of cyclooxygenase. The inventors attempted to reduce or at least alleviate the dose-related side effects associated with nimesulide by reducing the normally administered dose of nimesulide. In addition, low dose compositions have improved solubility, thus improved bioavailability, and are easier to formulate. In addition, the novel composition requires a smaller amount of excipients and therefore has a smaller size than conventionally available dosage forms, which in turn leads to better acceptance by patients. Preferably, the compositions of the present invention do not require the use of any ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Low dose pharmaceutical dosage form comprising nimesulide or its pharmaceutically acceptable salts, esters, solvates or hydrates thereof, along with one or more pharmaceutically acceptable excipient(s) are provided. The present invention also provides process of preparing such dosage forms and therapeutic methods of using such dosage forms. The low dose compositions 10 are designed to exhibit such bioavailability, which is effective in the treatment of NSAID indicated disorders particularly, which require long-term treatment regimens such as arthritis. Such compositions reduce the cost of therapy in diseases, which require long-term therapies, are easy to manufacture, and also result in the reduction of dose related side effects associated with nimesulide therapy.

Description

technical field [0001] The present invention relates to a novel low-dose pharmaceutical dosage form comprising nimesulide or a pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate or derivative thereof and one or more pharmaceutically acceptable excipients. The invention also provides methods of making such dosage forms and methods of treatment using such dosage forms. The low dose compositions are intended to demonstrate effective bioavailability in the treatment of NSAID indications, especially in treatments requiring long-term treatment regimens such as arthritis. The composition reduces the cost of treatment for diseases requiring long-term treatment, is easy to manufacture, and also leads to a reduction in dose-related side effects associated with nimesulide treatment. Background technique [0002] Cyclooxygenase-1 (COX-1) is an enzyme commonly found in various areas of the body, including inflammatory and gastric sites. The COX-1 enzyme of the stomach p...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/18A61K31/085
CPCA61K9/0019A61K9/2866A61K31/18A61K9/4858A61K9/0095A61K9/2018A61K9/2846A61K9/485A61P25/00A61P29/00A61P43/00A61K31/085
Inventor 拉杰什·贾殷库尔·昌德·吉恩达尔
Owner PANACEA BIOTEC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap